NEW YORK, Feb. 04, 2023 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors in Gossamer Bio, Inc. (“Gossamer” or the “Company”) GOSS. Those investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, extension 7980.

The investigation concerns whether Gossamer and certain of its officers and/or directors have engaged in securities fraud or other illegal business practices.

[Click here for information about joining the class action]

On December 6, 2022, Gossamer issued a press release announc[ing] Topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension (PAH).” Although the company admitted that seralutinib met the primary endpoint in the clinical trial, Wall Street analysts questioned its performance and found that the therapy was not above average Merck & Co. Inc.’s Sotatercept product.

As a result of this news, Gossamer’s stock price fell $6.93 per share, or 74.6%, to close at $2.36 per share on December 6, 2022.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris and Tel Aviv, is recognized as one of the leading law firms specializing in corporate, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, best known as Dean of the Class Bar Association, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues the tradition he founded and fights for the rights of victims of securities fraud, fiduciary breaches and corporate wrongdoing. The firm has recovered numerous multi-million dollar claims on behalf of group members. See www.pomlaw.com.

CONTACT:
Robert S Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980